Our Pricing

Switching from Injection to Oral Wegovy

Published on: June 03, 2026

If you're considering switching from injection to oral Wegovy UK, you're exploring a needle-free alternative that delivers the same active ingredient—semaglutide—in tablet form. At Cured Pharmacy, our UK-registered prescribers assess your eligibility and guide the transition protocol to ensure continuity of your weight management programme. Wegovy® Oral Tablets are now available from £20 off first order using code WEIGHTLOSSNEW

Understanding Oral Wegovy: Same Active Ingredient, Different Delivery

Wegovy® Oral Tablets contain semaglutide, the identical GLP-1 receptor agonist found in the injectable formulation licensed by the MHRA for chronic weight management [1]. The oral tablet uses an absorption enhancer called SNAC (salcaprozate sodium) to facilitate semaglutide uptake through the stomach lining, overcoming the digestive breakdown that typically prevents peptide absorption when taken by mouth.

Clinical trials demonstrate that oral semaglutide produces comparable weight loss outcomes to the injectable form when titrated to therapeutic doses. In the OASIS 1 trial, participants taking oral semaglutide 50 mg daily achieved an average 15.1% body weight reduction over 68 weeks, matching efficacy profiles seen with injectable semaglutide in the STEP trial programme [1][2].

The oral formulation requires specific administration protocols—taken on an empty stomach with no more than 120 ml of water, followed by a 30-minute fasting period before food or other medications. This precision ensures optimal absorption and therapeutic effect.

Who Can Switch from Injectable to Oral Wegovy?

Not all patients currently using injectable Wegovy qualify for transition to the oral formulation. Your UK prescriber will evaluate several clinical factors during your consultation, including your current dose stability, adherence patterns, gastrointestinal tolerance, and ability to follow the strict morning administration protocol required for oral semaglutide.

Patients who have reached a stable maintenance dose on injectable Wegovy and demonstrate consistent adherence are typically suitable candidates. Those experiencing injection site reactions, needle anxiety, or travel-related challenges with refrigerated storage may particularly benefit from the oral alternative [3].

Certain medical conditions may preclude oral Wegovy use. Patients with inflammatory bowel disease, gastroparesis, or conditions affecting gastric pH may experience reduced absorption. Your prescriber will review your complete medical history to determine suitability, as this is a prescription-only medication requiring clinical assessment by a UK-registered prescriber.

Contraindications and Precautions

Both oral and injectable Wegovy carry the same contraindications, including personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. The oral formulation adds specific considerations around gastric conditions and medication interactions that affect stomach pH, which your prescriber will assess during consultation.

The Switching Protocol: Dose Transition and Timing

Transitioning from injectable to oral Wegovy follows a structured protocol determined by your UK prescriber. The switch typically occurs after your final injectable dose, with oral therapy commencing the following day. Unlike initiating treatment from scratch, patients switching from injectable maintenance doses may start oral Wegovy at a higher titration level, depending on their current injectable dose and tolerance profile.

The oral formulation follows its own dose escalation schedule, typically starting at 3 mg daily and increasing gradually over 15-17 weeks to the target maintenance dose of 50 mg daily. This gradual titration minimises gastrointestinal side effects—the most common adverse events reported with oral semaglutide, including nausea, diarrhoea, and constipation [4].

Your prescriber may adjust the switching protocol based on your response to injectable Wegovy. Patients who experienced significant gastrointestinal effects during their initial injectable titration may benefit from a more conservative oral dose escalation. Regular monitoring during the transition period ensures therapeutic continuity and optimal tolerability.

What to Expect During the First Month

Most patients switching from injection to oral Wegovy maintain their weight loss trajectory without interruption, provided they adhere strictly to the morning administration protocol. Some individuals report mild transient nausea during the first fortnight as they adapt to the oral formulation, though this typically resolves as treatment continues. Your prescriber remains available throughout the transition for any clinical questions or dose adjustments.

Oral vs Injectable Wegovy: Efficacy and Convenience Compared

Clinical trial data show that oral and injectable semaglutide produce statistically comparable weight loss outcomes when patients reach therapeutic doses. The OASIS 1 trial demonstrated that oral semaglutide 50 mg daily achieved similar efficacy to injectable semaglutide 1 mg weekly, with both formulations activating the same GLP-1 receptor pathways that regulate appetite and glucose metabolism [1][2].

The primary difference lies in administration convenience and lifestyle fit. Injectable Wegovy requires once-weekly subcutaneous injection but offers flexible timing—patients can administer their dose at any time of day, with or without food. Oral Wegovy eliminates needles entirely but demands strict morning administration on an empty stomach, followed by a 30-minute wait before eating or taking other medications.

Cost considerations may influence your decision. At Cured Pharmacy, Wegovy® Oral Tablets start from £79.00, whilst injectable Wegovy starts from £79.00. Both options require prescription from a UK-registered prescriber following clinical assessment. Your choice should reflect your lifestyle, adherence capacity, and clinical response rather than price alone.

Managing Side Effects During the Transition

Gastrointestinal side effects remain the most frequently reported adverse events with both oral and injectable semaglutide formulations. During the switching period, some patients experience temporary recurrence of mild nausea or altered bowel habits as their body adapts to the oral delivery method, even if they tolerated injectable Wegovy well [4].

Practical strategies can minimise discomfort during transition. Taking your oral tablet immediately upon waking, before any morning activity, optimises absorption and may reduce nausea. Eating smaller, more frequent meals after the 30-minute fasting period helps manage gastrointestinal symptoms. Adequate hydration throughout the day supports digestive function and overall tolerability.

If side effects persist beyond the first fortnight or significantly impact your quality of life, contact your prescriber. Dose adjustments or a temporary pause in escalation may be appropriate. Never discontinue treatment abruptly without consulting your UK prescriber, as this may affect your weight management progress and metabolic stability.

When to Contact Your Prescriber

Seek immediate medical attention if you experience severe abdominal pain, persistent vomiting, signs of pancreatitis, or allergic reactions. For less urgent concerns—such as ongoing nausea, constipation lasting more than three days, or questions about your transition protocol—contact the Cured Pharmacy clinical team on (+44) 116 4646009. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) and UK prescribers provide ongoing support throughout your treatment journey.

Getting Started: Switching from Injection to Oral Wegovy at Cured Pharmacy

Beginning your transition from injectable to oral Wegovy requires a new clinical assessment by a UK-registered prescriber. At Cured Pharmacy, the online consultation takes under three minutes and covers your current injectable dose, treatment duration, weight loss progress, side effect history, and suitability for the oral formulation's administration requirements.

Our prescribers evaluate whether switching aligns with your clinical profile and weight management goals. If approved, your prescription is dispensed from our UK-registered pharmacy (GPhC 9012511) with discreet packaging and reliable delivery. All medicines supplied are genuine UK-licensed products—we never dispense unlicensed or imported alternatives.

Transparent pricing means you see the cost before consultation. Wegovy® Oral Tablets start from £79.00, with final pricing determined by your prescribed dose and treatment duration. Our lowest price guarantee ensures competitive UK rates without compromising pharmaceutical quality or clinical oversight. Start your free online consultation today to explore whether switching from injection to oral Wegovy suits your needs.

Scientific References

1. Knop, F. K., et al. (2023). Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 402(10403), 705–719. https://doi.org/10.1016/S0140-6736(23)01185-6 [accessed 13 August 2026]
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Medicines and Healthcare products Regulatory Agency. (2024). Wegovy 3 mg, 7 mg, 14 mg, 25 mg, 50 mg tablets: Summary of Product Characteristics. GOV.UK. Retrieved from https://www.gov.uk/ [accessed 13 August 2026]
4. Davies, M., et al. (2023). Gastrointestinal adverse events with oral semaglutide: analysis from the PIONEER trial programme. Diabetes, Obesity and Metabolism, 25(6), 1664–1675. https://doi.org/10.1111/dom.15025 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication or switching between formulations.